Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy - First Report from the Maestro Trial

J Christine Ye, Philip Boonstra, Erica L. Campagnaro, Matthew Pianko, Andrew Kin, Larry D Anderson, Jr., Brea Lipe, Moshe Talpaz, Jeffrey A. Zonder

Blood (2024) 144 (Supplement 1): 3379.

https://doi.org/10.1182/blood-2024-209505

Published: 2024

Journal Articles

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Terri L. Parker, Adam Rosenthal, Vaishali Sanchorawala, Heather J. Landau, Erica L. Campagnaro, Prashant Kapoor, Natalia Neparidze, Saulius Girnius, Patrick Hagen, Emma C. Scott, Antje Hoering, Brian G.M. Durie, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2024-208341

Published: 2024

Journal Articles

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Sikander Ailawadhi, Antje Hoering, J Christine Ye, Brea Lipe, Thomas R. Chauncey, Krisstina Gowin, David Calverley, Sarah A. Holstein, Erica L. Campagnaro, Adam Rosenthal, Jack Aiello, Saad Z. Usmani, Vincent Rajkumar, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3381.3.

https://doi.org/10.1182/blood-2024-209626

Published: 2024

Journal Articles

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2023) 142 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2023-181032

Published: 2023

Journal Articles

Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy

Blood (2019) 134 (Supplement_1): 3091.

https://doi.org/10.1182/blood-2019-130247

Published: 2019

Journal Articles

Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4350.

https://doi.org/10.1182/blood-2019-131037

Published: 2019

Journal Articles

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

J Christine Ye, MDMSc, Liying Chen, Jason Chen, MD, Brian Parkin, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica L. Campagnaro, MD, Dan Robinson, PhD, Yi-Mi Wu, Moshe Talpaz, MD, Jennifer Yesil, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MD, Veerabhadran Baladandayuthapani

Blood (2019) 134 (Supplement_1): 4360.

https://doi.org/10.1182/blood-2019-124135

Published: 2019

Journal Articles

A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy

J Christine Ye, MDMSc, Philip S Boonstra, PhD, Daniel F. Boyer, MD PhD, Larry D. Anderson, MD PhD, Brea C. Lipe, MD, Andrew Kin, MD, Erica L. Campagnaro, MD, Matthew J. Pianko, MD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 3191.

https://doi.org/10.1182/blood-2019-132204

Published: 2019

Journal Articles

A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 3169.

https://doi.org/10.1182/blood-2019-124870

Published: 2019

Journal Articles

Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)

Blood (2019) 134 (Supplement_1): 3119.

https://doi.org/10.1182/blood-2019-124298

Published: 2019

Journal Articles

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

Fares Alsawah, MD BS, MS, Samuel A. Merrill, MD PhD, Paula L. Bockenstedt, MD, Erica L. Campagnaro, MD, Sumana Devata, MD, Scott D. Gitlin, MD, Mark S Kaminski, MD, Alice M. Cusick, MD, Tycel J. Phillips, MD, Suman L. Sood, MD, Moshe Talpaz, MD, Albert Thomas Quiery, MD, Philip S Boonstra, PhD, Asra Z. Ahmed, MD, Ryan A. Wilcox, MD PhD

Blood (2018) 132 (Supplement 1): 1119.

https://doi.org/10.1182/blood-2018-99-116854

Published: 2018

Journal Articles

Amifostine Reduces High-Dose Melphalan Induced Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplant (HCT) for Plasma Cell Myeloma

Vinita Gupta, MD, Hulya Armutlugoynuk, MD, Anant Vatsayan, MD MBBS, Paolo F. Caimi, MD, Brenda Cooper, MD, Leland Metheny, MD, Ehsan Malek, MD, Erica L. Campagnaro, MD, Stan Gerson, MD, Marcos de Lima, MD, Hillard M. Lazarus, MD, Richard J Creger, PharmD

Blood (2015) 126 (23): 5491.

https://doi.org/10.1182/blood.V126.23.5491.5491

Published: 2015

Journal Articles

Falls in Older Adults with Multiple Myeloma

Tanya M Wildes, MD MSCI, Mark A Fiala, BS, CCRP, Ashley E Rosko, MD, Sascha Tuchman, MD, Emily Guerard, MD, Elizabeth K. O'Donnell, MD, Erica L. Campagnaro, MD, Keith Stockerl-Goldstein, MD, Ravi Vij, MD MBA

Blood (2015) 126 (23): 4485.

https://doi.org/10.1182/blood.V126.23.4485.4485

Published: 2015

Journal Articles

Phase I Trial of the Base – Excision Repair Blocker Methoxyamine (TRC-102) Combined with Fludarabine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Lymphoid Malignancies

Paolo Caimi, MD, Brenda Cooper, MD, Basem M. William, MD, Erica L Campagnaro, MD, Richard J. Creger, Pharm D, Manuel Afable, BSN, MD, Yan Xu, PhD, John Pink, PhD, Afshin Dowlati, Hillard M. Lazarus, MD, Marcos de Lima, MD, Stanton L. Gerson

Blood (2014) 124 (21): 4688.

https://doi.org/10.1182/blood.V124.21.4688.4688

Published: 2014

Journal Articles

Effects of Monoclonal Gammopathy of Undetermined Significance (MGUS) on Outcomes after Solid Organ Transplant

Teresa E Goebel, D.O., Nicholas K Schiltz, PhD, Aiswarya Chandran Pillai, MD/M.S., Paolo Caimi, MD, Siran M Koroukian, PhD, Kenneth J Woodside, MD, Erica L Campagnaro, MD

Blood (2014) 124 (21): 3507.

https://doi.org/10.1182/blood.V124.21.3507.3507

Published: 2014

Journal Articles

Increased Risk of Venous Thromboembolism in Primary Central Nervous System Lymphoma Patients Undergoing Therapy

Gayathri Ravi, MD, Brenda Cooper, MD, Erica L Campagnaro, MD, Basem M. William, MD, Richard J. Creger, Pharm D, Stanton L. Gerson, Marcos De Lima, MD, Hillard M. Lazarus, MD, Paolo Caimi, MD

Blood (2014) 124 (21): 5431.

https://doi.org/10.1182/blood.V124.21.5431.5431

Published: 2014

Journal Articles

All -Trans-Retinoic Acid (ATRA) Combined with Lithium As Treatment of Relapsed Non-Progranulocytic AML: Therapeutic Targeting Inhibition of the Glycogen Synthase Kinase 3-Beta (GSK3) Enzyme

Paolo Caimi, MD, Kalpana Gupta, PhD, Tammy Stefan, Brenda Cooper, MD, Basem M. William, MD, Erica L Campagnaro, MD, Richard J. Creger, Pharm D, Donna Kane, BSN, Stanton L. Gerson, Hillard M. Lazarus, MD, Marcos de Lima, MD, David N. Wald, MD PhD

Blood (2014) 124 (21): 5299.

https://doi.org/10.1182/blood.V124.21.5299.5299

Published: 2014

Journal Articles

Brentuximab Vedotin (BV) Does Not Impair Autologous Peripheral Blood Stem Cell Mobilization and Collection in Refractory/Relapsed CD30+ Lymphoma Patients Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplant (HDC-ASCT)

Manuel Afable, BSN, MD, Paolo F. Caimi, MD, Chitra Hosing, Marcos de Lima, MD, Issa F. Khouri, MD, Basem M. William, MD, Yago Nieto, MD PhD, Brenda W. Cooper, MD, Paolo Anderlini, MD, Erica L Campagnaro, MD, Stanton L. Gerson, Hillard M. Lazarus, MD, Richard E. Champlin, Uday R. Popat, MD

Blood (2014) 124 (21): 3854.

https://doi.org/10.1182/blood.V124.21.3854.3854

Published: 2014

Journal Articles

Second Umbilical Cord Blood Transplant (UCBT2) In Adult Patients With Engraftment Failure Or Autologous Hematopoiesis After UCBT

Paolo F. Caimi, MD, Ronald Sobecks, MD, Pingfu Fu, Ph., D., Brenda W Cooper, MD, Erica L. Campagnaro, MD, Basem M. William, MRCP, MD, Rolla Abu-Arja, MD, Merle J. Kolk, Richard J Creger, Pharm D, Hien Kim Duong, MD, Brian T. Hill, MD, PhD, Brian J. Bolwell, MD, Matt Kalaycio, MD, Marcos de Lima, MD, Hillard M. Lazarus, MD

Blood (2013) 122 (21): 2117.

https://doi.org/10.1182/blood.V122.21.2117.2117

Published: 2013

Journal Articles

Retrospective Study Of Incidence Of Thromboses In Chinese Versus African Americans With Multiple Myeloma

Radha Raghupathy, MD, Sabarish Ayyappan, MD, Dhivya Prabhakar, MD, Frankie KF Mo, Erica L. Campagnaro, MD, Kenny Ieng Kit Lei, MD, FRCP

Blood (2013) 122 (21): 1121.

https://doi.org/10.1182/blood.V122.21.1121.1121

Published: 2013

NARROW

Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy - First Report from the Maestro Trial

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy

Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy

A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

Amifostine Reduces High-Dose Melphalan Induced Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplant (HCT) for Plasma Cell Myeloma

Falls in Older Adults with Multiple Myeloma

Phase I Trial of the Base – Excision Repair Blocker Methoxyamine (TRC-102) Combined with Fludarabine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Lymphoid Malignancies

Effects of Monoclonal Gammopathy of Undetermined Significance (MGUS) on Outcomes after Solid Organ Transplant

Increased Risk of Venous Thromboembolism in Primary Central Nervous System Lymphoma Patients Undergoing Therapy

All -Trans-Retinoic Acid (ATRA) Combined with Lithium As Treatment of Relapsed Non-Progranulocytic AML: Therapeutic Targeting Inhibition of the Glycogen Synthase Kinase 3-Beta (GSK3) Enzyme

Brentuximab Vedotin (BV) Does Not Impair Autologous Peripheral Blood Stem Cell Mobilization and Collection in Refractory/Relapsed CD30+ Lymphoma Patients Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplant (HDC-ASCT)

Second Umbilical Cord Blood Transplant (UCBT2) In Adult Patients With Engraftment Failure Or Autologous Hematopoiesis After UCBT

Retrospective Study Of Incidence Of Thromboses In Chinese Versus African Americans With Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only